

16 May 2021 |

Quick Listen: Scrip's Five Must-Know Things

by [Ian Haydock](#)

In this week's podcast episode of Five Must-Know Things, hear about issues surrounding the proposed IP waiver for coronavirus vaccines, a trial delay for Novavax's COVID-19 vaccine, an ICER review of multiple myeloma drugs and Galapagos' efforts to refocus its R&D pipeline.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 14 May 2021, including: issues surrounding the proposed IP waiver for coronavirus vaccines; a trial delay for [Novavax, Inc.](#)'s COVID-19 vaccine; an ICER review of multiple myeloma drugs; and [Galapagos NV](#)'s efforts to refocus its R&D pipeline.

These and all other podcasts are available on the Informa Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#) - and also now on [Spotify Podcasts](#) - and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Speed Bumps Ahead For IP Waiver But Will It Nudge Voluntary Licensing?](#)" - Scrip, 12 May, 2021.)

(Also see "[India's COVID-19 Nightmare And How Pharma Is Holding Up](#)" - Scrip, 6 May, 2021.) Starts at 2:43

(Also see "[After Another Covid Vaccine Delay, Novavax's Opportunity Is Shrinking](#)" - Scrip, 11 May, 2021.) Starts at 4:25

(Also see "[*BCMA Drug Prices For Multiple Myeloma Don't Match Their Benefit, ICER Concludes*](#)" - Scrip, 12 May, 2021.) Starts at 6:19

(Also see "[*Galapagos Puts Faith In Refocused Pipeline To Regain Investor Confidence*](#)" - Scrip, 11 May, 2021.) Starts at 8:21

[Click here to explore this interactive content online](#) ✨